Alder Biopharmaceuticals Inc buy stratec
Start price
06.11.18
/
50%
€12.72
Target price
04.11.21
€25.26
Performance (%)
32.88%
End price
05.11.21
-
Summary
This prediction is currently being closed. With a performance of 32.88% the BUY prediction by stratec is a big success. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alder Biopharmaceuticals Inc | - | - | - | - |
| iShares Core DAX® | -3.509% | -8.747% | -0.997% | 48.496% |
| iShares Nasdaq 100 | -2.782% | -0.632% | 14.223% | 78.812% |
| iShares Nikkei 225® | -2.038% | -6.841% | 24.866% | 51.559% |
| iShares S&P 500 | -2.598% | -2.230% | 9.200% | 60.509% |
Comments by stratec for this prediction
In the thread Alder Biopharmaceuticals Inc diskutieren
Alder auf dem Weg, eine Best-in-Class-Therapie gegen Migräne zu entwickeln.
Eptinezumab wird derzeit in mehreren globalen, randomisierten, zulassungsrelevanten Phase-3-Studien untersucht, um seine Wirksamkeit und Sicherheit in der Migräneprävention zu bewerten. Bislang wurden mehr als 3.100 Patienten in das klinische Entwicklungsprogramm aufgenommen.
H. Lundbeck A/S (OTC:HLUKF) has agreed to acquire Alder BioPharmaceuticals (NASDAQ:ALDR) for $18 per share in cash plus one non-tradeable Contingent Value Right (CVR) for an additional $2 per share if migraine med eptinezumab is approved by the European Medicines Agency (EMA). The total value of the transaction is up to $1.95B.
In the thread Trading Alder Biopharmaceuticals Inc
Die von stratec gewählte maximale Laufzeit wurde überschritten